Journal article

The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer

AB Spurdle, B Goodwin, E Hodgson, JL Hopper, XQ Chen, DM Purdie, MRE McCredie, GG Giles, G Chenevix-Trench, C Liddle

Pharmacogenetics and Genomics | LIPPINCOTT WILLIAMS & WILKINS | Published : 2002

Abstract

CYP3A4 is involved in the metabolism of endogenous steroids, and an allelic variant, CYP3A4*1B, consisting of an A to G polymorphism within the 5'-flanking region termed the nifedipine-specific response element (NFSE) has been associated with high grade and advanced stage of prostate cancers. Because steroid hormone exposure is known to influence breast and ovarian cancer risk, we conducted case-control studies to assess the relationship between CYP3A4*1B and risk of breast or ovarian cancer. CYP3A4 NFSE genotype was determined in 951 breast cancer cases and 500 controls frequency matched for age and 488 ovarian cancer cases and 276 controls of similar age distribution. Case-control analyses..

View full abstract